68Ga-FAPI PET/CT 在原发灶不明头颈癌且 18F-FDG 阴性患者中的增益价值
本研究纳入 18 例 18F-FDG PET/CT 阴性的原发灶不明头颈癌患者,均于 1 周内行 18F-FDG 与 68Ga-FAPI PET/CT,并对 FAPI 阳性部位行活检病理。68Ga-FAPI PET/CT 在 7/18 例(38.89%)中检出原发灶,原发灶 SUVmax 均值 8.79(范围 2.60–16.50),肿瘤/对侧正常组织 SUVmax 比值均值 4.50(范围 2.17–8.21)。转移灶分析中,淋巴结与骨转移的 18F-FDG 与 68Ga-FAPI SUVmax 及靶本比差异均无统计学意义。
要点
- 18F-FDG 阴性的原发灶不明头颈癌患者中,68Ga-FAPI PET/CT 检出原发灶 7/18 例(38.89%)。
- 检出的原发灶位于鼻咽、腭扁桃体、下颌下腺及下咽,FAPI 摄取中度至 intense。
- 淋巴结与骨转移灶的 18F-FDG 与 68Ga-FAPI SUVmax 及靶本比差异均无统计学意义。
核心结论
- 68Ga-FAPI PET/CT 有潜力提高 18F-FDG 阴性原发灶不明头颈癌患者的原发灶检出率。
- 68Ga-FAPI 在转移灶评估方面的表现与 18F-FDG 相似。
研究设计与样本
- 单中心研究纳入 18 例 18F-FDG 阴性的原发灶不明头颈癌患者,其中男 16 例、女 2 例,中位年龄 55 岁(范围 24–72 岁)。
- 所有患者均在 1 周内接受 18F-FDG 与 68Ga-FAPI PET/CT 检查。
- 对 68Ga-FAPI PET/CT 阳性部位行活检与组织病理学检查。
主要发现
- 68Ga-FAPI PET/CT 在 7/18 例(38.89%)中检出原发灶。
- 7 例原发灶部位为鼻咽 1 例、腭扁桃体 2 例、下颌下腺 2 例、下咽 2 例。
- 原发灶 68Ga-FAPI 摄取为中度至 intensive,SUVmax 均值 8.79(范围 2.60–16.50),肿瘤/对侧正常组织 SUVmax 比值均值 4.50(范围 2.17–8.21)。
- 基于病灶分析共识别 65 个淋巴结和 17 个骨转移灶。
- 淋巴结转移灶 SUVmax:18F-FDG 9.05 ± 5.29 对比 68Ga-FAPI 9.08 ± 4.69(P = 0.975);骨转移灶 SUVmax:18F-FDG 8.11 ± 3.00 对比 68Ga-FAPI 6.96 ± 5.87(P = 0.478)。
临床怎么用
- 对 18F-FDG PET/CT 未检出原发灶的原发灶不明头颈癌患者,可考虑补充 68Ga-FAPI PET/CT 以尝试定位原发灶。
- 68Ga-FAPI PET/CT 阳性部位应行活检病理确认。
- 68Ga-FAPI 对转移灶的评估能力与 18F-FDG 相近,不能替代 18F-FDG 对转移灶的评估。
局限性
- 样本量小(18 例),结论需更大规模研究验证。
- 研究为单中心设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
18F-FDG PET/CT plays an important role in locating the primary tumor for patients with head and neck cancer of unknown primary (HNCUP). Nevertheless, in some cases it can be challenging to locate the primary malignancy on 18F-FDG PET/CT scans. Because 68Ga-radiolabeled fibroblast activation protein inhibitor (FAPI) PET/CT has promising results in detecting different tumor entities, our study aimed to evaluate the performance of 68Ga-FAPI PET/CT for detecting the primary tumor in HNCUP patients with negative 18F-FDG findings. Methods: Eighteen patients (16 men and 2 women; median age, 55 y; age range, 24-72 y) with negative 18F-FDG findings were enrolled in this study. All patients underwent 18F-FDG and 68Ga-FAPI PET/CT within 1 wk. Biopsy and histopathologic examinations were performed in the sites with positive 68Ga-FAPI PET/CT findings. Results:68Ga-FAPI PET/CT detected the primary tumor in 7 of 18 patients (38.89%). Among these 7 patients, primary tumor sites included the nasopharynx (n = 1), palatine tonsil (n = 2), submandibular gland (n = 2), and hypopharynx (n = 2). The primary tumors showed moderate to intensive uptake of 68Ga-FAPI (mean SUVmax, 8.79; range, 2.60-16.50) and excellent tumor-to-contralateral normal-tissue ratio (mean SUVmax ratio, 4.50; range, 2.17-8.21). In lesion-based analysis, 65 lymph nodes and 17 bone metastatic lesions were identified. The mean SUVmax of lymph node metastases was 9.05 ± 5.29 for 18F-FDG and 9.08 ± 4.69 for 68Ga-FAPI (P = 0.975); the mean SUVmax of bone metastases was 8.11 ± 3.00 for 18F-FDG and 6.96 ± 5.87 for 68Ga-FAPI (P = 0.478). The mean tumor-to-background ratios of lymph node and bone metastases were 10.65 ± 6.59 versus 12.80 ± 8.11 (P = 0.100) and 9.08 ± 3.35 versus 9.14 ± 8.40 (P = 0.976), respectively. Conclusion: We present the first evidence, to our knowledge, of a diagnostic role of 68Ga-FAPI PET/CT in HNCUP. Our study demonstrated that 68Ga-FAPI PET/CT has the potential to improve the detection rate of primary tumor in HNCUP patients with negative 18F-FDG findings. Moreover, 68Ga-FAPI had a performance in assessing metastases similar to that of 18F-FDG.
引用
- Gu B, Xu X, Zhang J, et al. The Added Value of 68Ga-FAPI PET/CT in Patients with Head and Neck Cancer of Unknown Primary with 18F-FDG-Negative Findings. J Nucl Med. 2021. PMID: 34593594. doi:10.2967/jnumed.121.262790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。